Research Paper
Midkine Controls Arteriogenesis by Regulating the Bioavailability of Vascular
Endothelial Growth Factor A and the Expression of Nitric Oxide Synthase
From November (2017), but only found it recently.
Source:
- Leukocyte domiciled midkine is decisive for collateral endothelial cell proliferation in arteriogenesis.
- Midkine controls the bioavailability of VEGFA mediating endothelial Nos1 and Nos3 expression.
- Nos1 and Nos3, relevant for endothelial cell proliferation, can substitute for each other.
http://www.ebiomedicine.com/article/S2352-3964(17)30463-2/fulltext#s0065
Or review full article as attached.
I don't have enough knowledge to know how to properly link it to Cellmid's ischemic disease program but it's in the same wider space (heart diseases).
http://www.cellmid.com.au/content_common/pg-kinera-ischemic-disease.seo
- Forums
- ASX - By Stock
- AN1
- Research: Midkine Controls Arteriogenesis by Regulating VEGFA Bioavailability and NOS Expression
Research: Midkine Controls Arteriogenesis by Regulating VEGFA Bioavailability and NOS Expression
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable